During the mid-decade drug development boom, some of the biggest winners were those contract service providers that are part
of the clinical supply chain. Contract development and manufacturing organizations (CDMOs) especially benefited from the dramatic
increase in early-stage compounds, which fed a surge in demand for process development, formulation development, and small-scale
The subsequent downturn in development activity, prompted by the drop in the availability of capital, has hit CDMOs particularly
hard. Double-digit declines have replaced double-digit increases, and many CDMOs are struggling to stay in business. No longer
able to float on a rising tide of predevelopment candidates, CDMOs are fighting for market share and survival.
In an effort to better understand the dynamics of and outlook for the CDMO industry, PharmSource recently completed a major
analysis of the clinical supply-chain market. We modeled the spend for clinical trial material (CTM) development and manufacturing,
including process development and manufacturing for active pharmaceutical ingredients (APIs), formulation and manufacturing
of dosage forms, and associated analytical activities (we excluded clinical packaging). We conducted extensive interviews
with buyers and sellers of clinical supply-chain services to understand the key behaviors and trends driving the industry.
The analysis goes into considerable depth on analytical chemistry activities.
Outsourcing highly penetrated
The PharmSource analysis estimates annual spend on CTM development and manufacture at about $9.3 billion, divided almost evenly
among process and formulation development, analytical development and testing, and manufacture of CTMs. The biggest bucket
of spending is in early development (preclinical and Phase 1), thanks to the large number of projects in the pipeline and
the high cost of API characterization and process development, especially for large-molecule compounds.
The most revealing aspect of the PharmSource analysis is the degree to which contract services have already penetrated the
clinical supply chain. We estimate that as much as two-thirds of CTM development and manufacturing expenditures are already
outsourced, a much larger proportion than we expected. The principal source for contract services' large share is the small
and mid-size biotechnology and pharmaceutical companies, which account for 88% of the outsourced spend. Small and mid-size
companies tend to be highly dependent on contract services and account for 75% of the candidates in the new drug development
pipeline. By contrast, large global companies, which account for one quarter of total development spending, make up just 12%
of outsourced spend.
The PharmSource model highlights the dilemma faced by CDMOs: they benefited greatly as the number of early development candidates
grew to more than 6000, a 55% increase from 1999, and are now suffering as the number of compounds slips back. Faced with
a shortage of capital, early-stage companies have been forced to halt work on many candidates and expend funds on remaining
candidates more cautiously. Our model projects that a 20% drop in the number of early-development candidates would result
in a 10–15% drop in outsourced development spending, which is in line with what we are seeing now throughout the marketplace.
There is good news, however. The PharmSource model also points to some substantial upside opportunities for the CDMO industry.
Most importantly, the continuing shift from small-molecule compounds to large molecules will likely be a significant boon
to the contract services. We expect that if large molecules grow to 30% of the pipeline from their current 22%, total outsourced
development spend will grow by 15%. Of course, where that spending takes place will shift as well. CDMOs specializing in large-molecule
API characterization, process development, and manufacture will increase their market share while small-molecule API manufacturers
will lose share.
The CDMO market is going through a significant restructuring as it adjusts to changing realities in the world of finance and
the bio/pharmaceutical industry. There will be significant opportunities for contract service providers as we come out of
the restructuring process, but there will definitely be winners and losers.
Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, tel. 703.383.4903, fax 703.383.4905, email@example.com